Search

Displaying results 4271 - 4280 of 4358 in total
  1. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes....

  2. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a...

  3. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  4. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.

  5. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  6. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  7. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  8. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  9. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other